Anhui Provincial Key Laboratory of Tumor Evolution and Intelligent Diagnosis and Treatment, Bengbu Medical University, Bengbu, Anhui 233030, China Clinical Testing and Diagnose Experimental Center, ...

For example, ravoxertinib and ulixertinib which inhibit MAPK1 and 3, are currently under clinical trial. In our data, MAPK3 is predicted to be enriched in the non-responders. Tongue squamous cell ...